MAR 0 9 2004

FAX 703-872-9306

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Peperwork Reduction Act of 1995, no persone are required to respond to a collection of information unless it contains a valid OMB control number,

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

Application No.	09/927,160
Filing Date	August 9, 2001
First Named Inventor	Sushma Pati
Examiner Name	Ann Marie Falk
Group Art Unit	1632
Attorney Docket No.	A-64580-4/AMP/JFB

Transmittal (1 page)

Amendment (8 pages)

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an epplication. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tredemark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Application No. 09/927,160 Filing Date August 9, 2001 **TRANSMITTAL** First Named Inventor Sushma Pati **FORM Examiner Name** Ann Marie Falk Group Art Unit 1632 (to be used for all correspondence after initial filing) Total Number of Pages in This Submission Attorney Docket No. A-64580-4/AMP/JFB

	,	ENCLOSURES (check all that apply)						
	Fee Transmittal Form	Assignment Papers (for an Application)		After Allowance Communication to Group				
D	Fee Attached	Drawing(s)		Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information				
	Amendment / Reply	Licensing-related Papers						
	After Final	Petition						
	Affidavits/declaration(s)	Petition to Convert to a Provisional Application		Status Letter				
	Extension of Time Request	Power of Attorney, Revocation Change of	\boxtimes	Other Enclosure(s)				
		Correspondence Address		(please identify below):				
	Express Abandonment Request	Terminal Disclaimer		Certificate of Transmission SB/97				
Information Disclosure Statement		Request for Refund						
Certified Copy of Priority Document(s)		CD, No. of CD(s)						
	Response to Missing Parts/ ncomplete Application	Remarks						
	Response to Missing Parts under 87 CFR 1.52 or 1.53							
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
Firm or Individual na		No. 39,118)						
Signature	John F.	Brades						
Date	March 9, 2004	<u> </u>						

MAR 0 9 2004

Attorney Docket No. A-64580-4/AMP/JFB

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named				
Inventor: Sushma Pati				
Appln. No.:	09/927,160	Examiner: Falk		
Filing Date:	August 9, 2001	Group Art Unit:	1632	
	TRANSGENIC ANIMALS PRODUCED			
	BY HOMOLOGOUS SEQUENCE			
Title:	TARGETING	Conf. No.:	4009	

Amendment Under 37 C.F.R §1.111 and Response to Restriction and/or Election Requirement

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants have considered the Office Action mailed February 5, 2004 (Paper No. 0204) and offer the following revised amendments and remarks. Applicants wish to thank the Examiner for giving them one month to submit a revised Amendment in compliance with 37 C.F.R. §1.121(b)(1)(ii). This Amendment is essentially the same as the Amendment filed December 1, 2003 with the exception that the amendment to the specification contains the full text of a replacement paragraph with markings to show all changes.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begin on page 3.

Remarks begin on page 5 of this paper.